Indolent/Low Grade Non-Hodgkin’s Lymphoma

FDA Approves New Indication for Ibrutinib in Waldenström’s Macroglobulinemia (02-24-2015)

The US Food and Drug Administration (FDA) today expanded the approved use of Imbruvica® (ibrutinib) for patients with Waldenström’s macroglobulinemia, a rare type of B-cell lymphoma. Imbruvica® is the first therapy indicated specifically for Waldenström’s... Continue Reading

HIV-Positive Patients with Lymphoma Should No Longer be Excluded From Receiving Blood Stem Cell Transplants as Treatment (12-17-2014)

HIV-positive patients with lymphoma were previously excluded from receiving autologous blood stem cell transplants as treatment, because of concern that these patients’ compromised immune systems would have a higher risk of infection and poor graft... Continue Reading

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment (07-21-2014)

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood... Continue Reading

Celiac Disease Associated with Higher Risk of Lymphoma (09-4-2013)

Individuals with celiac disease have an increased risk of lymphoma, particularly if they have a condition known as persistent villous atrophy, according to the results of a large cohort study published in the Annals of Internal Medicine.[1] Celiac disease... Continue Reading

Fractionated Zevalin Effective First-Line Treatment for Advanced Follicular Lymphoma (02-8-2013)

Fractionated radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is an effective first-line treatment for advanced stage follicular lymphoma and delivers high response rates in patients with high tumor burden, according to the results of... Continue Reading

Zevalin Effective as First-Line Treatment for Advanced Follicular Lymphoma (02-1-2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and well tolerated and induces a high rate of clinical and molecular responses when given as first-line treatment to patients with advanced stage follicular lymphoma, according... Continue Reading

Zevalin Effective in Follicular NHL Refractory to Rituximab (01-24-2013)

Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is effective in patients with non-Hodgkin’s lymphoma that is refractory to treatment with Rituxan® (rituximab), according to the results of a study published in the Journal of Clinical... Continue Reading

Consolidation with Zevalin Significantly Improves Progression-Free Survival in Advanced Follicular Lymphoma (01-10-2013)

Consolidation therapy with Zevalin® (ibritumomab tiuxetan) significantly prolongs progression-free survival and leads to high conversion rates from partial response to complete response in patients with advanced follicular lymphoma, according to the... Continue Reading

Several Effective Treatment Options for Early Follicular Lymphoma (09-4-2012)

The results of a recent study published in the Journal of Clinical Oncology challenge the standard treatment approach for follicular lymphoma—indicating that with proper staging at diagnosis, there are several treatment regimens that can bring a remission. Non-Hodgkin’s... Continue Reading

Treanda More Effective than Standard R-CHOP for Non-Hodgkin’s Lymphoma (06-12-2012)

The combination of Treanda® (bendamustine) and Rituxan® (rituximab) more than doubled progression-free survival compared with standard R-CHOP therapy among patients with indolent lymphoma and mantle cell lymphoma, according to the results of a multi-center,... Continue Reading

Next Page »